Osteosarcoma  >>  imatinib  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
imatinib / Generic mfg.
NCT00030667: Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Completed
2
100
US
imatinib mesylate, CGP 57148, Gleevec, Glivec, laboratory biomarker analysis, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma, Gastrointestinal Stromal Tumor, Lung Metastases, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
12/05
12/05
NCT00154388: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Completed
2
185
US, Europe, RoW
Imatinib mesylate
Novartis Pharmaceuticals
Life Threatening Diseases
01/07
01/07
NCT00031915: Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Completed
2
US
imatinib mesylate
National Cancer Institute (NCI)
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
 
05/07
NCT00062205: Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor

Completed
2
40
US
imatinib mesylate
City of Hope Medical Center, National Cancer Institute (NCI)
Sarcoma
06/07
06/07

Download Options